P868: A CIRCULATING SERUM MIRNAS-BASED MODEL TO PREDICT EARLY MORTALITY IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-BASED REGIMENS.

P868: A CIRCULATING SERUM MIRNAS-BASED MODEL TO PREDICT EARLY MORTALITY IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-BASED REGIMENS.

Bibliographic Details
Main Authors:	A. Puła, P. Robak, D. Jarych, D. Mikulski, I. Dróżdż, J. Szemraj, T. Robak
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846352.00706.35

Similar Items

The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
by: Anna Puła, et al.
Published: (2023-02-01)

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
by: Paweł Robak, et al.
Published: (2021-10-01)

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
by: Paweł Robak, et al.
Published: (2020-09-01)

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
by: Damian Mikulski, et al.
Published: (2021-12-01)

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib
by: Pawel Robak, et al.
Published: (2021-02-01)

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications
by: Anna Puła, et al.
Published: (2021-11-01)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
by: Pawel Robak, et al.
Published: (2019-04-01)

Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
by: Damian Mikulski, et al.
Published: (2022-10-01)

The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma.
by: Jingsong He, et al.
Published: (2014-01-01)

Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
by: Rafiye Ciftciler, et al.
Published: (2020-05-01)

The Effect of Bortezomib Regimen on Multiple Myeloma Patients Infected with COVID-19
by: Zahra Rezaeian, et al.
Published: (2023-10-01)

Effect of bortezomib regimens and daratumumab monotherapy on cellular immunity in multiple myeloma patients
by: Ashraf Kakoo, et al.
Published: (2021-06-01)

Survival and Prognosis Analysis of Bortezomib Based Regimen in Newly Diagnosed Super-aged Multiple Myeloma Patients
by: ZHAO Fengyi, LI Xin, ZHAN Xiaokai, ZHANG Jiajia, SHEN Man, TANG Ran, FAN Sibin, HUANG Zhongxia
Published: (2024-03-01)

Bortezomib-Based Regimens and Plasma Cell Leukemia
by: Ali Zahit Bolaman
Published: (2021-02-01)

Editorial: Novel targeted drugs for indolent lymphoid malignancies
by: Tadeusz Robak, et al.
Published: (2023-06-01)

Bortezomib in the management of multiple myeloma
by: Jacob P Laubach, et al.
Published: (2009-09-01)

TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB
by: Veronika Kodre, et al.
Published: (2008-04-01)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
by: Qian W, et al.
Published: (2020-01-01)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
by: Jingsong He, et al.
Published: (2020-12-01)

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

New bortezomib-based combination therapy for elimination of myeloma cells
by: Voll RE, et al.
Published: (2009-02-01)

Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma
by: Yanwei Luo, et al.
Published: (2020-11-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Bortezomib for the treatment of multiple myeloma patients
by: C Green, et al.
Published: (2009-06-01)

Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma
by: Aneta Szudy-Szczyrek, et al.
Published: (2022-02-01)

Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety
by: Yujia Zhai, et al.
Published: (2021-03-01)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
by: Xiao Liu, et al.
Published: (2022-09-01)

Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma
by: Liang Zhou
Published: (2022-03-01)

Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need
by: Przemysław Zygmunciak, et al.
Published: (2024-01-01)

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives
by: Iwona Hus, et al.
Published: (2022-03-01)

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
by: Pınar Ataca Atilla, et al.
Published: (2019-11-01)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
by: Angelica Ferro, et al.
Published: (2023-02-01)

VAD Chemotherapy Versus Bortezomib Containing Regimens As Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience
by: Aysun Senturk Yikilmaz, et al.
Published: (2020-10-01)

Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone
by: L. Wang, et al.
Published: (2015-08-01)

Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone
by: L. Wang, et al.
Published: (2015-06-01)

Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
by: Yuki Fujimoto, et al.
Published: (2021-11-01)

Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
by: Tadeusz Robak, et al.
Published: (2022-11-01)

The role of АВС transporters in drug resistance to bortezomib in multiple myeloma
by: L. A. Laletina, et al.
Published: (2019-04-01)

EP 3 368 868 Coriolis flowmeter
by: Henry, MP
Published: (2020)

Protein profiling in myeloma in vivo; Effects of bortezomib in a mouse model of myeloma
by: Edwards, C, et al.
Published: (2007)